PREVNAR + C295 ISS VACCINE FORMULATION IN INFANT BABOONS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本实验的目的是首次在婴儿狒狒中测试单独或联合免疫刺激DNA序列（C295 ISS和C295- pmxb）的商业肺炎球菌7价疫苗制剂（PREVNAR¿）的免疫原性。PREVNAR¿疫苗与C295 ISS或C295- pmxb联合在成年狒狒（952-PC-0）中进行了测试，结果显示是安全的。这项研究将有助于确定PREVNAR¿与C295 ISS或C295- pmxb疫苗制剂联合使用是否可以改善婴儿狒狒对肺炎球菌多糖抗原的抗体反应，这将有助于开发新的人类婴儿肺炎球菌疫苗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this experiment is to test for the first time in infant baboons the immunogenicity of a commercial pneumococcal 7-valent vaccine formulation (PREVNAR¿) alone, or in combination immunostimulatory DNA sequences (C295 ISS and C295-PMXB). PREVNAR¿ vaccine in combination with C295 ISS or C295-PMXB was tested in adult baboons (952-PC-0) and was shown to be safe. This study will help decide if PREVNAR¿ combined with C295 ISS or C295-PMXB vaccine formulation can elicit improved antibody responses in infant baboons to pneumococcal polysaccharide antigens, which will assist in the development of a new pneumococcal vaccine for human infants.